OBJECTIVES: To evaluate infectious disease outcomes and cost of care for lymphoma and myeloma patients admitted for infectious complications. To evaluate a Palm handheld as a tool for prospective data collection utilizing Pendragon Forms software. METHODS: Patients admitted to the Lymphoma/Myeloma service receiving anti-infective therapy for infectious diseases were followed. Targeted outcomes were collected prospectively during hospitalization and included length of hospitalization (days), adverse events attributed to the anti-infective, febrile days (= 38.3 °C), resolution of signs/symptoms, and survival. Financial data were collected for the time of hospitalization. RESULTS: Eleven patients have been enrolled. The average age of the patients is 57 years (range 40-80). The majority (64%) of the patients were female and 55% of the patients had lymphoma. The infection was microbiologically documented in 27%, clinically documented in 46%, and twenty-seven percent of patients had a fever of unknown origin. The average length of hospitalization was 9 days (range 3-27). One patient had an adverse event due to an anti-infective and included chills and rigors with amphotericin-B lipid complex. The average number of febrile days was 3 (range 1-8). Every patient except one had resolution of signs and symptoms of the infection. One patient died due to a viral pneumonia. The anti-infective utilized most frequently was imipenem/cilastatin. The average cost of hospitalization per patient was $22,438 (range $5,222.60-$53,398.95). The average cost of pharmaceuticals per patient was $6,947.50 (range $2,929.81-$18,642.82). CONCLUSIONS: Infectious complications in cancer patients can produce morbidity and mortality as well as be costly. Infectious disease outcomes can easily be collected utilizing a Palm handheld.